Policy paper: Myriad turns cancer genetic data into trade secrets
If the information Myriad Genetics has collected about breast cancer mutations remains proprietary, costs of gene tests could increase while quality declines, argues Robert Cook-Deegan, a policy researcher at Duke University in Durham, North Carolina. In a paper published today in the European Journal of Human Genetics, Cook-Deegan and co-authors John Conley, James Evans, and Daniel Vorhaus urge health-care payers and policy makers to encourage the company to share clinical data and proprietary algorithms. Read more
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells